keyword
MENU ▼
Read by QxMD icon Read
search

Late Onset Hypogonadism

keyword
https://www.readbyqxmd.com/read/29105668/-testosterone-replacement-therapy-and-cardiovascular-risk
#1
Giovanni Corona, Mauro Dicuio, Giulia Rastrelli, Alessandra Sforza, Mario Maggi
Late onset hypogonadism (LOH) is the most commonly used term to indicate the age-dependent reduction of testosterone. Sexual dysfunction represents the most important determinant for medical consultation and the most specific symptoms associated with LOH. In particular, data from the European Male Ageing Study (EMAS), a population-based survey on more than 3400 subjects, recognized that a triad of sexual symptoms (low libido and reduced spontaneous and sex-related erections) is the only syndromic association with decreased testosterone levels...
November 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29075365/antioxidant-and-antifibrotic-effect-of-a-herbal-formulation-in-vitro-and-in-the-experimental-andropause-via-nrf2-ho-1-signaling-pathway
#2
Woong Jin Bae, Guan Qun Zhu, Sae Woong Choi, Hyun Cheol Jeong, Fahad Bashraheel, Kang Sup Kim, Su Jin Kim, Hyuk Jin Cho, U Syn Ha, Sung Hoo Hong, Ji Youl Lee, Hyun-A Oh, Hye Cheong Koo, Do Ram Kim, Sung Yeoun Hwang, Sae Woong Kim
The Korean herbal formulation Ojayeonjonghwan is used for improving late-onset hypogonadism (LOH) symptoms such as erectile dysfunction (ED). A previous research suggested that a modified Ojayeonjonghwan (KH-204) could be used as an alternative to the treatment for ED. The pharmacological effects were examined in different conditions, including in vitro and in vivo. We measured the survival rate of TM3 Leydig cells under the oxidative stress condition. The s.c. injection of leuprorelin was used to induce androgen deprivation...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28980739/serum-testosterone-levels-in-male-hypogonadism-why-and-when-to-check-a-review
#3
REVIEW
Mark Livingston, Anura Kalansooriya, Andrew J Hartland, Sudarshan Ramachandran, Adrian Heald
AIM: Although "late onset hypogonadism", a condition that includes low testosterone and symptoms, is common in men over the age of 40 years, diagnosis is not clear cut amongst non-specialists. It is the aim of this review to provide an up to date picture of how this state should be diagnosed and managed. METHODS: We aim to describe how primary and secondary hypogonadism should be excluded before the diagnosis of late onset hypogonadism is reached. As laboratory testosterone measurements are essential the current pitfalls such as inappropriate sample collection and the use of population derived reference ranges are expanded...
October 5, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28924487/a-novel-stop-mutation-p-gln22-of-dax1-nr0b1-results-in-late-onset-x-linked-adrenal-hypoplasia-congenita
#4
Judith Gerards, Michael M Ritter, Elke Kaminsky, Andreas Gal, Wolfgang Hoeppner, Marcus Quinkler
DAX1 (NR0B1) is an orphan nuclear receptor, which plays an important role in development and function of the adrenal glands and gonads. Mutations in DAX1 cause X-linked adrenal hypoplasia congenita (X-linked AHC), which is characterized by adrenal insufficiency (AI) and hypogonadotropic hypogonadism (HHG). Affected boys present with adrenal failure usually in childhood and, later in life, with delayed puberty. However, patients with a late-onset form of X-linked AHC have also been described in the past years...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28741070/late-onset-x-linked-adrenal-hypoplasia-dax-1-nr0b1-two-new-adult-onset-cases-from-a-single-center
#5
Nikolaos Kyriakakis, Tolulope Shonibare, Julie Kyaw-Tun, Julie Lynch, Carlos F Lagos, John C Achermann, Robert D Murray
PURPOSE: DAX-1 (NR0B1) is an orphan nuclear receptor, which plays a critical role in development and regulation of the adrenal gland and hypothalamo-pituitary-gonadal axis. Mutations in NR0B1 lead to adrenal hypoplasia congenita (AHC), hypogonadotropic hypogonadism (HH) and azoospermia in men. Presentation is typically with adrenal insufficiency (AI) during infancy or childhood. To date only eight cases/kindreds are reported to have presented in adulthood. METHODS: We describe two new cases of men with DAX-1 mutations who presented in adulthood and who were diagnosed at a large University Hospital...
October 2017: Pituitary
https://www.readbyqxmd.com/read/28721216/switch-to-restoration-therapy-in-a-testosterone-treated-central-hypogonadism-with-erythrocytosis
#6
B Cangiano, C Cacciatore, L Persani, M Bonomi
We describe a case of severe erythrocytosis caused by testosterone replacement therapy in a 66-year-old man affected with hypogonadotropic hypogonadism (HH) determining osteoporosis, resolved by switching to restoration therapy with clomiphene citrate. The patient complained fatigue, loss of libido and defective erections and a spontaneous vertebral fracture despite bisphosphonate therapy and vitamin D supplementation. The examinations proved isolated HH and he was therefore treated with testosterone gel with regression of specific manifestations but elevated hemoglobin and hematocrit values...
2017: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/28721133/late-onset-hypogonadism
#7
REVIEW
Piotr Dudek, Jarosław Kozakowski, Wojciech Zgliczyński
In Poland, the number of men over the age of 50 years exceeds 6 million. It is estimated that about 2-6% of this population develops symptoms of late-onset hypogonadism (LOH). In men, testosterone deficiency increases slightly with age. LOH is a clinically and biochemically defined disease of older men with serum testosterone level below the reference parameters of younger healthy men and with symptoms of testosterone deficiency, manifested by pronounced disturbances of quality of life and harmful effects on multiple organ systems...
June 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28649100/-aging-and-homeostasis-sex-hormones-and-aging
#8
Keizo Ohnaka
The decline in sex hormones along with aging is suggested to be involved in age-associated diseases such as cardiovascular diseases, osteoporosis, and dementia. The decrease of estrogen level after menopause is related to osteoporosis in addition to climacteric disturbance in women, while that of testosterone to sarcopenia, osteoporosis and late-onset hypogonadism in men. New treatment strategy is expected for targeting age-associated diseases against the decreased level of sex hormones.
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28593169/atherosclerosis-is-associated-with-erectile-function-and-lower-urinary-tract-symptoms-especially-nocturia-in-middle-aged-men
#9
Akira Tsujimura, Ippei Hiramatsu, Yusuke Aoki, Hirofumi Shimoyama, Taiki Mizuno, Taiji Nozaki, Masato Shirai, Kazuhiro Kobayashi, Yoshiaki Kumamoto, Shigeo Horie
BACKGROUND: Atherosclerosis is a systematic disease in which plaque builds up inside the arteries that can lead to serious problems related to quality of life (QOL). Lower urinary tract symptoms (LUTS), erectile dysfunction (ED), and late-onset hypogonadism (LOH) are highly prevalent in aging men and are significantly associated with a reduced QOL. However, few questionnaire-based studies have fully examined the relation between atherosclerosis and several urological symptoms. MATERIALS AND METHODS: The study comprised 303 outpatients who visited our clinic with symptoms of LOH...
June 2017: Prostate International
https://www.readbyqxmd.com/read/28497912/testosterone-replacement-therapy-long-term-safety-and-efficacy
#10
REVIEW
Giovanni Corona, Alessandra Sforza, Mario Maggi
Recent position statements and guidelines have raised the distinction between a true and false, age-related hypogonadism (HG) or late-onset hypogonadism (LOH). The former is the consequence of congenital or acquired "organic" damage of the brain centers or of the testis. The latter is mainly secondary to age-related comorbidities and does not require testosterone (T) therapy (TTh). In addition, concerns related to cardiovascular (CV) safety have further increased the scepticism related to TTh. In this paper, we reviewed the available evidence supporting the efficacy of TTh in non-organic HG and its long term safety...
August 2017: World Journal of Men's Health
https://www.readbyqxmd.com/read/28495861/testosterone-treatment-and-cardiovascular-and-venous-thromboembolism-risk-what-is-new
#11
G Corona, M Dicuio, G Rastrelli, E Maseroli, F Lotti, A Sforza, M Maggi
In men, testosterone (T) production declines as a function of ageing. Late-onset hypogonadism (LOH) is the most commonly used term to indicate this age-related condition. In LOH, the relative clinical significance and the potential benefit of testosterone treatment (TTh) are still the subject of strong criticisms in the scientific community. The debate is further complicated by the recent position statement of the US Food and Drug Administration (FDA) emphasizing that, in LOH, the benefits and safety of TTh have not been fully established...
August 2017: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
https://www.readbyqxmd.com/read/28472914/low-testosterone-levels-and-metabolic-syndrome-in-aging-male
#12
Rodrigo Blaya, Patrícia Blaya, Luiza Rhoden, Ernani Luis Rhoden
Advances in medicine and progressive improvements in the health of the general population in developed countries have led to considerable increases in life expectancy over recent years. Metabolic syndrome (MetS) affects approximately 25% of the adult population and its prevalence is increasing all over the world. Central obesity plays an important role in emergence of MetS. Some studies have suggested that there may be link between low Total Testosterone levels and emergence of MetS. The objective of this review is to analyze the complex network of interactions between MetS and low testosterone levels in elderly men, considering etiologic, diagnostic, and therapeutic aspects...
May 3, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28470687/correlates-and-prevalence-of-hypogonadism-in-patients-with-early-and-late-onset-type-2-diabetes
#13
Y Li, M Zhang, X Liu, W Cui, S Rampersad, F Li, Z Lin, P Yang, H Li, C Sheng, X Cheng, S Qu
This study aims to compare the prevalence of hypogonadism between male patients with early-onset type 2 diabetes mellitus (T2DM) and late-onset type 2 diabetes. A total of 122 male patients with early-onset T2DM (diagnosis age ≤40 years) and 100 male patients with late-onset T2DM (diagnosis age >40 years) were recruited from our in-patient department between 1 January 2013 and 28 December 2015. Serum FSH, LH, testosterone, lipid profile, uric acid, HbA1c, and beta-cell function were determined in blood samples...
May 3, 2017: Andrology
https://www.readbyqxmd.com/read/28437248/protective-effect-of-calretinin-on-testicular-leydig-cells-via-the-inhibition-of-apoptosis
#14
Wendan Xu, Qian Zhu, Bei Zhang, Shan Liu, Xiaonan Dai, Chao Gao, Li Gao, Yugui Cui
The core mechanism of Late-onset hypogonadism (LOH) is the deficiency of androgen due to the functional and quantitative decline of testicular Leydig cells. Here we explored the protective effect of calretinin, a Ca(2+)-binding protein, on Leydig cells. We found in MLTC-1 cells transfected with LV-calb2, the cell viability and optical density (OD) were higher (p<0.05), cells in the S phase of the cell cycle were increased (p<0.01) and p-ERK1/2 and p-AKT levels were significantly higher (p<0.01 and p<0...
April 2017: Aging
https://www.readbyqxmd.com/read/28409902/testosterone-level-and-endothelial-dysfunction-in-patients-with-vasculogenic-erectile-dysfunction
#15
Y A Omar, S E Younis, I Y Ismail, A I El-Sakka
The association between endothelial dysfunction and late onset hypogonadism (LOH) in patients with vasculogenic erectile dysfunction (ED) is not yet well settled. Our objective was to assess the association between LOH and endothelial dysfunction in patients with vasculogenic ED. Throughout 2014-2015 a total of 90 men were enrolled in this cross-sectional observational study. Of them 60 patients with a clinical diagnosis of ED were further subdivided into two equal groups: patients with vasculogenic ED and LOH (A); patients with vasculogenic ED and euogonadal (B)...
May 2017: Andrology
https://www.readbyqxmd.com/read/28367841/a-higher-score-on-the-aging-males-symptoms-scale-is-associated-with-insulin-resistance-in-middle-aged-men
#16
Nobuya Hamanoue, Makito Tanabe, Tomoko Tanaka, Yuko Akehi, Junji Murakami, Takashi Nomiyama, Toshihiko Yanase
An age-associated androgen decrease and its pathological conditions are defined as late-onset hypogonadism (LOH). Among the various symptoms associated with LOH, a visceral fat increase is strongly associated with relatively low levels of testosterone. However, few studies have investigated the relationship between the Aging Males' Symptoms (AMS) scores and metabolic abnormalities. Thus, we aimed to clarify this relationship by investigating the relationship between AMS scores and various markers in blood. During routine health examinations in 241 middle-aged males (52...
May 30, 2017: Endocrine Journal
https://www.readbyqxmd.com/read/28333214/-forever-young-testosterone-replacement-therapy-a-blockbuster-drug-despite-flabby-evidence-and-broken-promises
#17
Andrea Busnelli, Edgardo Somigliana, Paolo Vercellini
In the last decade, testosterone replacement therapy (TRT) has been increasingly prescribed to treat a controversial condition known as 'late-onset hypogonadism (LOH)'. This syndrome is diagnosed in men who, for no discernible reason other than older age, obesity or ill health have serum testosterone concentrations below the normal range for healthy young men and report one or more of the following symptoms: muscle weakness or wasting, mood, behaviour and cognition-related symptoms and sexual function or libido impairment...
April 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28295504/testosterone-therapy-has-positive-effects-on-anthropometric-measures-metabolic-syndrome-components-obesity-lipid-profile-diabetes-mellitus-control-blood-indices-liver-enzymes-and-prostate-health-indicators-in-elderly-hypogonadal-men
#18
O Canguven, R A Talib, W El Ansari, D-J Yassin, M Salman, A Al-Ansari
To alleviate late-onset hypogonadism, testosterone treatment is offered to suitable patients. Although testosterone treatment is commonly given to late-onset hypogonadism patients, there remains uncertainty about the metabolic effects during follow-ups. We assessed the associations between testosterone treatment and wide range of characteristics that included hormonal, anthropometric, biochemical features. Patients received intramuscular 1,000 mg testosterone undecanoate for 1 year. Patient anthropometric measurements were undertaken at baseline and at each visit, and blood samples were drawn at each visit, prior to the next testosterone undecanoate...
March 10, 2017: Andrologia
https://www.readbyqxmd.com/read/28284037/a-novel-dax-1-mutation-in-two-male-siblings-presenting-with-precocious-puberty-and-late-onset-hypogonadotropic-hypogonadism
#19
Yanxia Liu, Jinlei Yuan, Huijuan Zhang, Yanyan Jiang, Guijun Qin
Background The DAX-1 gene is associated with X-linked adrenal hypoplasia congenita (AHC). Our objective was to compare the DAX-1 gene sequence of two male siblings exhibiting different clinical manifestations of AHC. Methods Clinical features were analyzed and laboratory data were collected from both siblings. Genomic DNA was extracted from the peripheral blood leukocytes of the siblings and their parents and the DAX-1 gene exons and intron-flanking regions were amplified by the polymerase chain reaction. The DAX-1 gene sequences were compared following sequencing...
March 1, 2017: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/28078221/testosterone-replacement-therapy-and-voiding-dysfunction
#20
REVIEW
Wesley Baas, Tobias S Köhler
Testosterone replacement therapy (TRT) represents an increasing popular treatment option for men with late-onset hypogonadism (LOH). Because of unsubstantiated beliefs of testosterone's effect on the prostate, the FDA has recently placed a warning on testosterone products, stating that TRT may worsen benign prostatic hyperplasia (BPH). Within this review article we have demonstrated the current understanding of the physiology of testosterone and its relationship with prostatic and lower urinary tract physiology...
December 2016: Translational Andrology and Urology
keyword
keyword
13559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"